These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 22439933)

  • 1. Activated ALK collaborates with MYCN in neuroblastoma pathogenesis.
    Zhu S; Lee JS; Guo F; Shin J; Perez-Atayde AR; Kutok JL; Rodig SJ; Neuberg DS; Helman D; Feng H; Stewart RA; Wang W; George RE; Kanki JP; Look AT
    Cancer Cell; 2012 Mar; 21(3):362-73. PubMed ID: 22439933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroblastoma and Its Zebrafish Model.
    Zhu S; Thomas Look A
    Adv Exp Med Biol; 2016; 916():451-78. PubMed ID: 27165366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proliferation and Survival of Embryonic Sympathetic Neuroblasts by MYCN and Activated ALK Signaling.
    Kramer M; Ribeiro D; Arsenian-Henriksson M; Deller T; Rohrer H
    J Neurosci; 2016 Oct; 36(40):10425-10439. PubMed ID: 27707976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells.
    Schönherr C; Ruuth K; Kamaraj S; Wang CL; Yang HL; Combaret V; Djos A; Martinsson T; Christensen JG; Palmer RH; Hallberg B
    Oncogene; 2012 Dec; 31(50):5193-200. PubMed ID: 22286764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ALK is a MYCN target gene and regulates cell migration and invasion in neuroblastoma.
    Hasan MK; Nafady A; Takatori A; Kishida S; Ohira M; Suenaga Y; Hossain S; Akter J; Ogura A; Nakamura Y; Kadomatsu K; Nakagawara A
    Sci Rep; 2013 Dec; 3():3450. PubMed ID: 24356251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma.
    Moore NF; Azarova AM; Bhatnagar N; Ross KN; Drake LE; Frumm S; Liu QS; Christie AL; Sanda T; Chesler L; Kung AL; Gray NS; Stegmaier K; George RE
    Oncotarget; 2014 Sep; 5(18):8737-49. PubMed ID: 25228590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma.
    Berry T; Luther W; Bhatnagar N; Jamin Y; Poon E; Sanda T; Pei D; Sharma B; Vetharoy WR; Hallsworth A; Ahmad Z; Barker K; Moreau L; Webber H; Wang W; Liu Q; Perez-Atayde A; Rodig S; Cheung NK; Raynaud F; Hallberg B; Robinson SP; Gray NS; Pearson AD; Eccles SA; Chesler L; George RE
    Cancer Cell; 2012 Jul; 22(1):117-30. PubMed ID: 22789543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MYCN and ALKF1174L are sufficient to drive neuroblastoma development from neural crest progenitor cells.
    Schulte JH; Lindner S; Bohrer A; Maurer J; De Preter K; Lefever S; Heukamp L; Schulte S; Molenaar J; Versteeg R; Thor T; Künkele A; Vandesompele J; Speleman F; Schorle H; Eggert A; Schramm A
    Oncogene; 2013 Feb; 32(8):1059-65. PubMed ID: 22484425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ALK pERKs up MYCN in neuroblastoma.
    Lindner S; Henssen A; Astrahantseff K; Schulte JH
    Sci Signal; 2014 Oct; 7(349):pe27. PubMed ID: 25351246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma.
    Cazes A; Lopez-Delisle L; Tsarovina K; Pierre-Eugène C; De Preter K; Peuchmaur M; Nicolas A; Provost C; Louis-Brennetot C; Daveau R; Kumps C; Cascone I; Schleiermacher G; Prignon A; Speleman F; Rohrer H; Delattre O; Janoueix-Lerosey I
    Oncotarget; 2014 May; 5(9):2688-702. PubMed ID: 24811913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New strategies in neuroblastoma: Therapeutic targeting of MYCN and ALK.
    Barone G; Anderson J; Pearson AD; Petrie K; Chesler L
    Clin Cancer Res; 2013 Nov; 19(21):5814-21. PubMed ID: 23965898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Copy number status and mutation analyses of anaplastic lymphoma kinase (ALK) gene in 90 sporadic neuroblastoma tumors.
    Bagci O; Tumer S; Olgun N; Altungoz O
    Cancer Lett; 2012 Apr; 317(1):72-7. PubMed ID: 22085494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in neuroblastoma.
    Umapathy G; El Wakil A; Witek B; Chesler L; Danielson L; Deng X; Gray NS; Johansson M; Kvarnbrink S; Ruuth K; Schönherr C; Palmer RH; Hallberg B
    Sci Signal; 2014 Oct; 7(349):ra102. PubMed ID: 25351247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MYCN promotes the expansion of Phox2B-positive neuronal progenitors to drive neuroblastoma development.
    Alam G; Cui H; Shi H; Yang L; Ding J; Mao L; Maltese WA; Ding HF
    Am J Pathol; 2009 Aug; 175(2):856-66. PubMed ID: 19608868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ALK(R1275Q) perturbs extracellular matrix, enhances cell invasion and leads to the development of neuroblastoma in cooperation with MYCN.
    Ueda T; Nakata Y; Yamasaki N; Oda H; Sentani K; Kanai A; Onishi N; Ikeda K; Sera Y; Honda ZI; Tanaka K; Sata M; Ogawa S; Yasui W; Saya H; Takita J; Honda H
    Oncogene; 2016 Aug; 35(34):4447-58. PubMed ID: 26829053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The growth inhibitory effect of 17-DMAG on ALK and MYCN double-positive neuroblastoma cell line.
    Yi B; Yang J; Wang L
    Tumour Biol; 2014 Apr; 35(4):3229-35. PubMed ID: 24293393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Critical Role for GAB2 in Neuroblastoma Pathogenesis through the Promotion of SHP2/MYCN Cooperation.
    Zhang X; Dong Z; Zhang C; Ung CY; He S; Tao T; Oliveira AM; Meves A; Ji B; Look AT; Li H; Neel BG; Zhu S
    Cell Rep; 2017 Mar; 18(12):2932-2942. PubMed ID: 28329685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.
    Lu J; Guan S; Zhao Y; Yu Y; Woodfield SE; Zhang H; Yang KL; Bieerkehazhi S; Qi L; Li X; Gu J; Xu X; Jin J; Muscal JA; Yang T; Xu GT; Yang J
    Cancer Lett; 2017 Aug; 400():61-68. PubMed ID: 28455243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New insights into the genetics of neuroblastoma.
    Sridhar S; Al-Moallem B; Kamal H; Terrile M; Stallings RL
    Mol Diagn Ther; 2013 Apr; 17(2):63-9. PubMed ID: 23329364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ALK upregulates POSTN and WNT signaling to drive neuroblastoma.
    Huang M; Fang W; Farrel A; Li L; Chronopoulos A; Nasholm N; Cheng B; Zheng T; Yoda H; Barata MJ; Porras T; Miller ML; Zhen Q; Ghiglieri L; McHenry L; Wang L; Asgharzadeh S; Park J; Gustafson WC; Matthay KK; Maris JM; Weiss WA
    Cell Rep; 2024 Mar; 43(3):113927. PubMed ID: 38451815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.